MedTrace Logo

Safety of Recombinant Hybrid GMZ 2 [GLURP + MSP 3] Blood Stage Malaria Vaccine

NCT00424944 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2008-04-03

No results posted yet for this study

Summary

The study aims to show that the candidate malaria vaccine GMZ2 is as safe as the already publicly used vaccine against rabies. 40 adult male Gabonese volunteers will be enrolled and randomly allocated to receive either malaria vaccine or rabies vaccine without the investigator or the participants knowing what they received. They will receive 3 doses each at one month intervals, and will be followed up for one year to evaluate safety parameters.

This is the first time this product will be tested in Africa

Conditions

Interventions

BIOLOGICAL

GMZ2 (malaria vaccine)

100 micrograms of GMZ2 in each vaccination

BIOLOGICAL

GMZ2 malaria vaccine

100 micrograms of GMZ2

BIOLOGICAL

Verorab vaccine

Anti-rabies vaccine

Sponsors & Collaborators

  • African Malaria Network Trust

    lead NETWORK

Principal Investigators

  • Peter Kremsner, MD, PhD · Medical research Unit, Albert Schweitzer Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-06-30
Primary Completion
2008-07-31
Completion
2008-08-31

Countries

  • Gabon

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00424944 on ClinicalTrials.gov